Dr Reddy's Labs selects Amazon Web Services as preferred cloud provider

Published On 2023-07-11 07:00 GMT   |   Update On 2023-07-11 07:00 GMT
Advertisement

New Delhi: Amazon Web Services (AWS) on Monday announced that Dr. Reddy’s Laboratories has selected it as preferred cloud provider to help provide access to affordable and innovative medicines.

As part of the collaboration, the company has migrated its SAP platform entirely onto AWS.

"By centralising the platform on the world’s leading cloud, Dr. Reddy’s will accelerate the development of new healthcare applications, grow its digital platform to help the organisation serve more than 1.5 billion patients by 2030 around the world, and enable healthcare providers to better track the progress of patients," according to a statement.

Advertisement

Since 2019, Dr. Reddy’s has been progressively creating and migrating digital applications to AWS to automate the company’s IT infrastructure.

Read also: Dr Reddy's Labs gets CDSCO panel nod to manufacture, market Ferric Carboxymaltose Inj to treat iron deficiency

"Leveraging AWS, Dr. Reddy’s has made healthcare more accessible by launching new applications faster, to provide better service to its customers," the statement said.

With AWS, Dr. Reddy’s aims to reduce application development time by 30 per cent, improve internal operations, accelerate improvements in generic drug manufacturing processes, and drive new areas of innovation

Read also: Dr Reddys Labs step down arm to establish bio-manufacturing facility in Hyderabad

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.

Read also: Revise Phase IV clinical trial protocol of Nimesulide Granules for oral suspension: CDSCO Panel Tells Dr Reddys

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News